PF-06260933
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527680

CAS#: 1811510-56-1 (free base)

Description: PF-06260933 is a potent and highly selective inhibitor of MAP4K4.


Price and Availability

Size
Price

100mg
USD 1250
1g
USD 3750
Size
Price

200mg
USD 1950
2g
USD 4950
Size
Price

500mg
USD 2650
5g
USD 8450

PF-06260933, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 527680
Name: PF-06260933
CAS#: 1811510-56-1 (free base)
Chemical Formula: C16H13ClN4
Exact Mass: 296.0829
Molecular Weight: 296.758
Elemental Analysis: C, 64.76; H, 4.42; Cl, 11.95; N, 18.88


Related CAS #: 1883548-86-4 (2HCl)   1811510-56-1 (free base)   2118243-34-6 (HCl)  

Synonym: PF06260933; PF 06260933; PF-06260933

IUPAC/Chemical Name: 5-(4-Chlorophenyl)-[3,3']bipyridinyl-6,6'-diamine

InChi Key: KHPCIHZXOGHCLY-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H13ClN4/c17-13-4-1-10(2-5-13)14-7-12(9-21-16(14)19)11-3-6-15(18)20-8-11/h1-9H,(H2,18,20)(H2,19,21)

SMILES Code: NC1=C(C2=CC=C(Cl)C=C2)C=C(C3=CC=C(N)N=C3)C=N1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Roth Flach RJ, Skoura A, Matevossian A, Danai LV, Zheng W, Cortes C, Bhattacharya SK, Aouadi M, Hagan N, Yawe JC, Vangala P, Menendez LG, Cooper MP, Fitzgibbons TP, Buckbinder L, Czech MP. Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis. Nat Commun. 2015 Dec 21;6:8995. doi: 10.1038/ncomms9995. PubMed PMID: 26688060; PubMed Central PMCID: PMC4703891.

2: Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Carlo AA, Conrad R, Cortes C, Dow RL, Dowling MS, El-Kattan A, Ford K, Guimarães CR, Hepworth D, Jiao W, LaPerle J, Liu S, Londregan A, Loria PM, Mathiowetz AM, Munchhof M, Orr ST, Petersen DN, Price DA, Skoura A, Smith AC, Wang J. Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment. ACS Med Chem Lett. 2015 Oct 6;6(11):1128-33. doi: 10.1021/acsmedchemlett.5b00215. eCollection 2015 Nov 12. PubMed PMID: 26617966; PubMed Central PMCID: PMC4645242.